Prospects of stem cell therapy in osteoarthritis

Regenerative Medicine

Volumn 6, Issue 3, 2011, Pages 351-366

  Roberts, Sally ^a,e   Genever, Paul ^a,b   McCaskie, Andrew ^a,c   Bari, Cosimo De ^a,d  

^a Arthritis Research UK Tissue Engineering Centre   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

articular cartilage; bone; immunomodulatory; mesenchymal stem cell; stem cell niches

Indexed keywords

ASCORBIC ACID; DEXAMETHASONE; GAMMA INTERFERON; GLYCEROL 2 PHOSPHATE; POLYDIOXANONE; POLYGLYCOLIC ACID; POLYLACTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT STEM CELL; ARTICULAR CARTILAGE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOLOGICAL ACTIVITY; BIOPROCESS; BONE DEVELOPMENT; CARTILAGE CELL; CELL ACTIVATION; CELL ACTIVITY; CELL ADHESION; CELL DIFFERENTIATION; CELL HOMING; CELL LINEAGE; CELL PROLIFERATION; CELL REGENERATION; CELL RENEWAL; CELL TYPE; CHONDROGENESIS; CULTURE MEDIUM; DEVELOPMENTAL STAGE; DRUG MECHANISM; EMBRYONIC STEM CELL; FETAL STEM CELL; GOOD MANUFACTURING PRACTICE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOMODULATION; INNER CELL MASS; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOARTHRITIS; PERICYTE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL EXPANSION; STEM CELL NICHE; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TISSUE ENGINEERING; TOTIPOTENT STEM CELL; TREATMENT RESPONSE;

HUMANS; JOINTS; OSTEOARTHRITIS; STEM CELL NICHE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 79955820579     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.11.21     Document Type: Review

References (147)

1. Schroeppel JP, Crist JD, Anderson HC, Wang J: Molecular regulation of articular chondrocyte function and its significance in osteoarthritis. Histol. Histopathol. 26(3), 377-394 (2011).
2. Sun HB: Mechanical loading, cartilage degradation, and arthritis. Ann. NY Acad. Sci. 1211, 37-50 (2010).
3. Goldring SR, Goldring MB: Bone and cartilage in osteoarthritis: is whats best for one good or bad for the other? Arthritis Res. Ther. 12, 143 (2011).
4. Evangelou E, Valdes AM, Kerkhof HJ, Styrkarsdottir U, Zhu Y, Meulenbelt I: Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. Ann. Rheum. Dis. 70, 349-355 (2011).
5. Malchau H, Herberts P, Garellick G, Soderman P, Eisler T: Prognosis of total hip replacement: update of results and risk-ratio analysis for revision and re-revision from the Swedish National Hip Arthoplasty Register 1979-2000. Scientific Exhibition. Presented at: 69th Annual Meeting of the American Academy of Orthopaedic Surgeons. Dallas, TX, USA, 11-15 June 2002.
6. Chen FH, Tuan RS: Mesenchymal stem cells in arthritic diseases. Arthritis Res. Ther. 10(5), 223 (2008).
7. Johnson MH, McConnell JM: Lineage allocation and cell polarity during mouse embryogenesis. Sem. Cell Dev. Biol. 15(5), 583-597 (2004). (Pubitemid 38953955)
8. Evans MJ , Kaufman MH: Establishment in culture of pluripotent cells from mouse embryos. Nature 292(5819), 154-156 (1981). (Pubitemid 11050741)
9. Martin GR: Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl Acad. Sci. USA 78(12), 7634-7638 (1981). (Pubitemid 12186197)
10. Bongso A, Fong CY, Ng SC, Ratnam S: Isolation and culture of inner cell mass cells from human blastocytes. Hum. Reprod. 9(11), 2110-2117 (1994). (Pubitemid 24354458)
11. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al.: Embryonic stem cell lines derived from human blastocytes. Science 282(5391), 1145-1147 (1998). (Pubitemid 28516247)
12. Nichols J, Zevnik B, Anastassiadis K et al.: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 95(3), 379-391 (1998). (Pubitemid 28507326)
13. Chambers I, Colby D, Robertson M et al.: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113(5), 643-655 (2003). (Pubitemid 36694189)
14. Rodda DJ, Chew JL, Lim LH et al.: Transcriptional regulation of nanog by OCT4 and SOX2. J. Biol. Chem. 280(26), 24731-24737 (2005). (Pubitemid 40934562)
15. Johansson H, Simonsson S: Core transcription factors, Oct4 Sox2 and Nanog, individually form complexes with nucleophosmin (Npm1) to control embryonic stem (ES) cell fate determination. Aging 2(11), 1-8 (2010).
16. Boyer LA, Plath K, Zeitlinger J et al.: Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441(7091), 349-353 (2006). (Pubitemid 44050199)
17. Lee JH, Hart SR, Skalnik DG: Histone deacetylase activity is required for embryonic stem cell differentiation. Genesis 38(1), 32-38 (2004). (Pubitemid 38197607)
18. Meshorer E, Misteli T: Chromatin in pluripotent embryonic stem cells and differentiation. Nat. Rev. Mol. Cell Biol. 7(7), 540-546 (2006). (Pubitemid 44036459)
19. Efroni S, Duttagupta R, Cheng J et al.: Global transcription in pluripotent embryonic stem cells. Cell Stem Cell 2(5), 437-447 (2008). (Pubitemid 351598083)
20. Houbaviy HB, Murray MF, Sharp PA: Embryonic stem cell-specific microRNAs. Dev. Cell 5(2), 351-358 (2003). (Pubitemid 37006477)
21. Kanellopoulou C, Muljo SA, Kung AL et al.: Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 19(4), 489-501 (2010). (Pubitemid 40256280)
22. Kim NW, Piatyszek MA, Prowse KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193), 2011-2015 (1994).
23. Miura T, Mattson MP, Roa MS: Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 3(6), 333-343 (2010).
24. Zhong XY, Zhang B, Asadollahi R, Low SH, Holzgreve W: Umbilical blood stem cells: what to expect. Ann. NY Acad. Sci. 1205, 17-22 (2010).
25. Gluckman E, Broxmeyer HA, Auerbach AD et al.: Hematopoietic reconstruction in a patient with Fanconis anemia by means of umilical-cord blood from an HLA-identical sibling. N. Engl. J. Med. 321(17), 1174-1178 (1989). (Pubitemid 19255814)
26. Quintin A, Schizas C, Scaletta C et al.: Isolation and in vitro chondrogenic potential of human fetal spine cells. J. Cell. Mol. Med. 13, 2559-2569 (2009).
27. ODonoghue K, Fisk NM: Fetal stem cells. Best Pract. Res. Clin. Obstet. Gynaecol. 18(6), 853-875 (2004). (Pubitemid 40012024)
28. Gucciardo L, Lories R, Ochsenbein-Kolble N, Done E, Zwijsen A, Deprest J: Fetal mesenchymal stem cells: isolation, properties and potential use in perinatology and regenerative medicine. Br. J. Obstet. Gynaecol. 116(2), 166-172 (2009).
29. Pappa KL, Anganou NP: Novel sources of fetal stem cells: where do they fit on the deveopmental continuum? Regen. Med. 4(3), 423-433 (2009).
30. Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG: Isolation and characterization of mesenchymal stem cells from the sub-amniotic human ubilical lining membrane. Stem Cells Dev. 19(4), 491-502 (2010).
31. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006). (Pubitemid 44233629)
32. Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007). (Pubitemid 350138099)
33. Wernig M, Meissner A, Foreman R et al.: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151), 318-324 (2007). (Pubitemid 47080337)
34. Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858), 1917-1920 (2007).
35. Kim K, Doi A, Wen B: Epigenetic memory in induced pluripotent stem cellls. Nature 467(7313), 285-290 (2010).
36. Pasi CE, Dedreli-Oz A, Negrini S et al.: Genomic instability in induced stem cells. Cell Death Diff. 18(5), 745-753 (2011).
37. Huangfu D, Osafune K, Maehr R et al.: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 26(11), 1269-1275 (2008).
38. Woltjen K, Michale IP, Mohseni P et al.: A piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458(7239), 766-770 (2009).
39. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K: Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239), 771-775 (2009).
40. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S: Promotion of direct reprogramming by transformation-deficient Myc. Proc. Natl Acad. Sci. USA 107(32), 14152-14157 (2010).
41. Flores I, Blasco MA: The role of telomeres and telomerase in stem cell aging. Fed. Eur. Biochem. Soc. Lett. 584(17), 3826-3830 (2010).
42. Scadden DT: The stem cell niche as an entity of action. Nature 441(7097), 1075-1079 (2006). (Pubitemid 43990719)
43. Friedenstein AJ, Chailakhjan RK, Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Res. 3(4), 393-403 (1970).
44. Caplan AI: Mesenchymal stem cells. J. Orthop. Res. 9(5), 641-650 (1991).
45. Horwitz EM, Le Blanc K, Dominici M et al.: Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7(5), 393-395 (2005). (Pubitemid 41671625)
46. Bianco P, Robey PG, Saggio I, Riminucci M: Mesenchymal stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity and significance in incurable skeletal disease. Hum. Gene Ther. 21(9), 1057-1066 (2010).
47. da Silva ML, Chagatelles PC, Nardi NB: Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119(11), 2204-2213 (2006). (Pubitemid 43960310)
48. Pittenger MF, Mackay AM, Beck SC et al.: Multilineage potential of human mesenchymal stem cells. Science 284, 143-147 (1999). (Pubitemid 29282067)
49. Dominici M, Le Blanc K, Mueller I et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular position statement. Cytotherapy 8(4), 315-317 (2006). (Pubitemid 44269669)
50. Simmons PJ, Torok-Storb B: Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78(1), 55-62 (1991).
51. Jones EA, Kinsey SE, English A et al.: Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum. 46(12), 3349-3360 (2002). (Pubitemid 35453547)
52. Sacchetti B, Funari A, Michienzi S et al.: Self-renewing osteoprogenitors in bone marrow sinusoids can organise a hematopoietic microenvironment. Cell 131(2), 324-336 (2007). (Pubitemid 47592917)
53. Barzilay R, Melamed E, Offen D: Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells 27(10), 2590-2515 (2009).
54. Frith J, Genever P: Transcriptional control of mesenchymal stem cell differentiation. Transf. Med. Hemother. 35(3), 216-227 (2008).
55. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell. Biochem. 64(2), 295-312 (1997). (Pubitemid 27065443)
56. de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W: Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 19, 389-394 (2000).
57. Zhou G, Zheng Q, Engin F et al.: Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc. Natl Acad. Sci. USA 103(50), 19004-19009 (2006). (Pubitemid 350002818)
58. Cheng A, Genever PG: SOX9 determines RUNX transactivity by directing intracellular degradation. J. Miner. Res. 25(12), 2404-2413 (2010).
59. Si YL, Zhao YL, Hao HJ, Fu XB, Han WD: MSCs: biological characteristics, clinical applications and their outstanding concerns. Ageing Res. Rev. 10(1), 93-103 (2011).
60. Hoogduijn MJ, Popp F, Verbeek R et al.: The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. Int. Immunopharmacol. 10(12), 1496-1500 (2010).
61. Liu Y, Mu R, Wang S et al.: Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 12(6), R210 (2010).
62. Di Nicola M, Carlo-Stella C, Magni M et al.: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002). (Pubitemid 34534559)
63. Popp FC, Eggenhofer E, Renner P et al.: Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transplant Immunol. 20, 55-60 (2008).
64. Bartholomew A, Sturgeon C, Siatskas M et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Haematol. 30, 42-48 (2002). (Pubitemid 34059216)
65. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005). (Pubitemid 40223708)
66. Yao C, Sakata D, Esaki Y et al.: Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15, 633-640 (2009).
67. Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML: Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp. Cell Res. 316, 3109-3123 (2010).
68. Sbano P, Cuccia A, Mazzanti B et al.: Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch. Dermatol. Res. 300(3), 115-124 (2008).
69. Mias C, Lairez O, Trouche E et al.: Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricle fibrosis after myocardial infarction. Stem Cells 27(11), 2734-2743 (2009).
70. Yagi H, Soto-Guitierrez A, Parekkadan B et al.: Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 19(6), 667-679 (2010).
71. Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25, 2739-2749 (2007). (Pubitemid 350127858)
72. Ding C, Cicuttini F, Cooley H, Boon C, Jones G: Natural history of knee cartilage defects and factors affecting change. Arch. Int. Med. 166(6), 651-658 (2006).
73. Messner K, Maletius W: The long-term prognosis for severe damage to weight-bearing cartilage in the knee: a 14 year clinical and radiographic follow-up in 28 young athletes. Acta Orthop. Scand. 67(2), 165-168 (1996). (Pubitemid 26140405)
74. Shelbourne KD, Jari S, Gray T: Outcome of untreated traumatic articular cartilage defects of the knee: a natural history study. J. Bone Joint Surg. Am. 85A(Suppl. 2), 8-16 (2003). (Pubitemid 36535040)
75. Shapiro F, Koide S, Glimcher MJ: Cell origin and differentiation in the repair of full-thickness defects of articular cartilage. J. Bone Joint Surg. Am. 75A(4), 532-553 (1993). (Pubitemid 23171742)
76. Eltawil NM, De Bari C, Achan P, Pitzalis C, DellAccio F: A novel in vivo murine model of cartilage regeneration. Age and strain-dependent outcome after joint surface injury. Osteoarthritis Cart. 17(6), 695-704 (2009).
77. Lee CH, Cook JL, Mendelson A, Moioli EK, Yao H, Mao JJ: Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 7(376), 440-448 (2010).
78. Jones EA, English A, Henshaw K et al.: Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal stem cells in inflammatory and degenerative arthritis. Arthritis Rheum. 50(3), 315-317 (2004).
79. De Bari C, DellAccio F, Tylzanowski P, Luyten FP: Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 44(8), 1928-1942 (2001). (Pubitemid 32758241)
80. De Bari C, DellAccio F, Vandenabeele F, Vermeesch JR, Raymackers JM, Luyten F: Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J. Cell Biol. 160(6), 909-918 (2003). (Pubitemid 36350845)
81. De Bari C, DellAccio F, Luyten F: Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum. 44(1), 85-95 (2001). (Pubitemid 32113122)
82. De Bari C, DellAccio F, Vanlauwe J et al.: Mesenchymal multipotency of adult human periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum. 54(4), 1209-1221 (2006). (Pubitemid 43672933)
83. Nakahara H, Dennis JE, Bruder SP, Haynesworth SE, Lennon DP, Caplan A: In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp. Cell Res. 195, 492-503 (1991). (Pubitemid 121006351)
84. Sakai D: Biological treatment: future beyond cell transplantation. Proc. World Forum Spine Res. (2010) (Epub ahead of print).
85. Zuk PA, Zhu M, Ashjian P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 13, 4279-4295 (2002). (Pubitemid 35471185)
86. Dowthwaite GP, Bishop JC, Redman SN et al.: The surface of articular cartilage contains a progenitor cell population. J. Cell Sci. 117, 889-897 (2004). (Pubitemid 38386946)
87. Williams R, Khan IM, Richardson K et al.: Identification and clonal characterisation of a progenitor cell sub-population in normal human articular cartilage. PLoS One 5(10), 1-14 (2010).
88. Shi S , Gronthos S: Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J. Bone Miner. Res. 18(4), 696-704 (2003). (Pubitemid 36899319)
89. De Bari C, Pringle S, Pitzalis C, DellAccio F: The stem cell niche: a new target in medicine. Curr. Opin. Orthop. 17(5), 398-404 (2006). (Pubitemid 44342150)
90. da Silva ML, Caplan AI, Nardi NB: In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26(9), 2287-2299 (2008).
91. Khan IM, Bishop JC, Gilbert S, Archer CW: Clonal chondroprogenitors maintain telomerase activity and Sox9 expression during extended monolayer culture and retain chondrogenic potential. Osteoarthritis Cart. 17, 518-528 (2009).
92. Koelling S, Krugel J, Irmer M et al.: Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell 4(4), 324-335 (2009).
93. Koelling S, Miosge N: Sex differences of chondrogenic progenitor cells in late stages of osteoarthritis. Arthritis Rheum. 62(4), 1077-1087 (2010).
94. English A, Jones EA, Corscadden D et al.: A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis. Rheumatology 46, 1676-1683 (2007). (Pubitemid 350018489)
95. Yarak S, Okamoto OK: Human adipose-derived stem cells: current challenges and clinical perspectives. An. Bras. Dermatol. 85(5), 647-656 (2010).
96. Kurth TB, DellAccio F, Crouch V, Augello A, Sharpe PT, De Bari C: Functional mesenchymal stem cell niches in the adult knee joint synovium in vivo. Arthritis Rheum. (2010) (Epub ahead of print).
97. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331(6), 889-895 (1994). (Pubitemid 24299869)
98. Meisel HJ, Siodla V, Ganey T, Minkus Y, Hutton WC, Alasevic O: Clinical experience in cell-based therapeutics: disc chondrocyte transplantation -a treatment for degenerated or damaged intervertebral disc. Biomol. Eng. 24, 5-21 (2006). (Pubitemid 46216157)
99. Bajada S, Harrison PE, Ashton BA, Cassar-Pullicino VN, Ashammakhi N, Richardson JB: Successful treatment of refactory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. J. Bone Joint Surg. Br. 89, 1382-1386 (2007). (Pubitemid 350157325)
100. Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W: Safety and compliations reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr. Stem Cell Res. Ther. 5, 81-93 (2010).
101. Bhosale A, Kuiper JH, Johnson WEB, Harrison P, Richardson JB: Midterm to long-term longitudinal outcome of autologous chondrocyte implantation in the knee joint - a multilevel analysis. Am. J. Sports Med. 20(10), 1-8 (2009).
102. Hollander AP, Dickinson SC, Sims TJ, Soranzo C, Pavesio A: Quantitative analysis of repair tissue biopsies following chondrocyte implantation. Tissue Eng. Cart. Bone 249, 218-233 (2003). (Pubitemid 41329053)
103. Haddo O, Mahroof S, Higgs D et al.: The use of chondrogide membrane in autologous chondrocyte implantation. Knee 11, 51-55 (2004). (Pubitemid 38221232)
104. Zheng M-H, Willers C, Kirilak L et al.: Matrix-induced autologous chondrocyte implantation (MACI): biological and histological assessment. Tissue Eng. 13(4), 737-746 (2007). (Pubitemid 46651504)
105. Kreuz PC, Muller S, Ossendorf C, Kaps C, Erggelet C: Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results. Arthritis Res. Ther. 11(2), R33 (2009).
106. Warnke PH, Springer ING, Wiltfang J et al.: Growth and transplantation of a custom vascularised bone graft in a man. Lancet 364, 766-769 (2005).
107. Macchiarini M, Jungebluth P, Go T et al.: Clinical transplantation of a tissue-engineered airway. Lancet 372(9655), 2023-2030 (2008).
108. De Bari C, Pitzalis C, DellAccio F: Reparative medicine: from tissue engineering to joint surface regeneration. Regen. Med. 1(1), 59-69 (2006).
109. DellAccio F, De Bari C, Luyten FP: Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis Rheum. 44(7), 1608-2619 (2001).
110. Roberts S, Hollander AP, Caterson B, Menage J, Richardson JB: Matrix turnover in human cartilage repair tissue in autologous chondrocyte implantation. Arthritis Rheum. 44, 2586-2598 (2001). (Pubitemid 33049337)
111. Saris DBF, Vanlauwe J, Victor J et al.: Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. Am. J. Sports Med. 36(2), 235-246 (2008).
112. Saris DB, Vanlauwe J, Victor J et al.: Treatment of symptomatic cartilage defects of the knee: characterized chondrocyte implantation results in better clinical outcome at 36 months in a randomized trial compared with microfracture. Am. J. Sports Med. 37(Suppl. 1), 10S-19S (2009).
113. Tyndall A, Walker UA, Cope A et al.: Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res. Ther. 9(1), 301 (2007).
114. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M: Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cart. 10, 199-206 (2002). (Pubitemid 34189569)
115. De Bari C, DellAccio F, Luyten F: Failure of in vitro-differentiated mesenchymal stem cells from the synovial membrane to form ectopic stable cartilage in vivo. Arthritis Rheum. 50(1), 142-150 (2004). (Pubitemid 38084298)
116. Scotti C, Tonnarelli B, Papadimitropoulos A et al.: Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc. Natl Acad. Sci. USA 107(16), 7251-7256 (2010).
117. Pelttari K, Winter A, Steck E et al.: Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum. 54(10), 3254-3266 (2006). (Pubitemid 44622096)
118. De Bari C, DellAccio F, Karystinou A et al.: A biomarker-based mathematical model to predict bone-formation potency of human synovial and periostoeal mesenchymal stem cells. Arthritis Rheum. 58(1), 240-250 (2008).
119. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T: Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 52(8), 2521-2529 (2005). (Pubitemid 41117441)
120. Karystinou A, DellAccio F, Kurth TB et al.: Distinict mesenchymal progenitor cell subsets in the adult human synovium. Rheumatology 48(9), 1057-1064 (2009).
121. Fickert S, Fiedler J, Brenner RE: Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining cell surface markers. Arthritis Res. Ther. 6(5), R422-R432 (2004).
122. Trommelmans L, Selling J, Dierickx K: A critical assessment of the directive on tissue engineering of the European Union. Tissue Eng. 13(4), 667-672 (2007). (Pubitemid 46651497)
123. Michaux G, Van Passel D: Advanced therapy medicinal products - the rules are harmonised in Europe. Reg. Affairs J. Pharma 18(8), 1-10 (2007).
124. Kent J, Pfeffer N: Regulating the collection and use of fetal stem cells. Br. Med. J. 332(7546), 866-867 (2006). (Pubitemid 44365578)
125. Barker M: Stem cells: fast and furious. Nature 458(7241), 962-965 (2009).
126. Evangelou E, Loughlin J, Spector TD: Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteosrthritis on chromosome 7q22. Ann. Rheum. Dis. 70(2), 349-355 (2011).
127. Meulenbelt I, Bos SD, Chapman K et al.: Meta-analysis of genes modulating intracellular T3 bio-availability reveal a possible role for the DIO3 gene in osteoarthritis susceptibility. Br. Med. J. 70(1), 164-167 (2011).
128. Sambrook PN, MacGregor AJ, Spector TD: Genetic influences on cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins. Arthritis Rheum. 42(2), 366-372 (1999). (Pubitemid 29072855)
129. Videman T, Batti MC, Ripatti S, Gill K, Manninen H, Kaprio J: Determinants of the progression in lumbar degeneration: a 5 year follow-up study of adult male monozygotic twins. Spine 31(6), 671-678 (2006).
130. Bajada S, Marshall MJ, Wright KT, Richardson JB, Johnson WEB: Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45, 726-735 (2010).
131. Stenderup K, Justesen J, Clauusen C, Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33, 919-926 (2003). (Pubitemid 37543568)
132. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F: Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 46(3), 704-713 (2002). (Pubitemid 34218142)
133. Røsland GV, Svendsen A, Torsvik A et al.: Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 69(13), 5331-5339 (2009).
134. Torsvik A, Røsland GV, Svendsen A et al.: Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track -letter. Cancer Res. 70(15), 6393-6396 (2010).
135. Prockop DJ, Brenner H, Fibbe WE et al.: Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 12(5), 576-578 (2010).
136. Tarte K, Gaillard J, Lataillade JJ et al.: Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 115(8), 1549-1553 (2010).
137. Rubio D, Garcia-Castro J, Martin MC et al.: Spontaneous human stem cell transformation. Cancer Res. 68(8), 3035-3039 (2005). (Pubitemid 40524580)
138. Wright K, El Masri W, Osman A, Chowdury J, Johnson WEB: Bone marrow cell therapy for SCI. Stem Cell Rev. (2010) (Epub ahead of print).
139. Kishk NA, Gabr H, Hamdy S et al.: Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil. Neural Repair 24(8), 702-708 (2010).
140. Delorme B, Ringe J, Pontikoglou C et al.: Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 27, 1142-1151 (2009).
141. Oldershaw RA, Baxter MA, Lowe ET et al.: Directed differentiation of human embryonic stem cells towards chondrocytes. Nat. Biotechnol. 28(11), 1187-1196 (2010).
142. Barker M: Testing times for stem cells. Nature 463(7282), 719-719 (2010).
143. Caplan AI: Mesenchymal stem cells: the past, the present, the future. Cartilage 1(1), 6-9 (2010).
144. Caplan AI, Bruder SP: Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol. Med. 7(6), 259-264 (2001). (Pubitemid 32545522)
145. Arthritis Care: OA Nation: the most comprehensive UK report of people with osteoarthritis www.arthritiscare.org.uk/@3235/Forhealthprofessionals/ OANation
146. The National Collaborating Centre for Chronic Conditions: Osteoarthritis. National clinical guideline for care and management in adults www.nice.org.uk/nicemedia/pdf/CG59NICEguideline.pdf
147. European Medicines Agency CAT: Reflection paper on stem cell-based medicinal products www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2010/03/WC500079932.pdf